RxDoctor Payments Data

Patricia Myers, MD

Neurology · Charleston, SCNPI 1063501898

Payments from drug & device makers

$920in general payments, 2019–2025

Across 51 payments — averaging $18.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$361
  • UCB, Inc.$127
  • Abbott$86
  • Amneal Pharmaceuticals LLC$45
  • Novartis$39
  • Amgen$39
  • plus $223 from 11 others

What the payments were for

  • Food & beverage$920100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$920 in reported general payments places this provider in the 45th percentile of 270 neurology providers in South Carolina.

See all neurology providers in South Carolina

Medicare billing

Part B allowed, 2024
$65,402
Medicare patients
287
Services billed
601

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Aimovig AutoinjectorErenumab-Aooe49$42,232
QuliptaAtogepant16$28,113
Nurtec OdtRimegepant Sulfate12$15,465
Lacosamide43$9,623
Levetiracetam112$4,377
Butalbital-Acetaminophen-CaffeButalb/Acetaminophen/Caffeine64$4,273
Pregabalin45$3,245
Sumatriptan Succinate12$2,812
Memantine Hcl93$2,545
Carbidopa-LevodopaCarbidopa/Levodopa50$2,327
Primidone28$1,942
Pramipexole DihydrochloridePramipexole Di-Hcl35$1,833
Donepezil Hcl161$1,622
Topiramate153$1,384
Quetiapine Fumarate89$1,355

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieQulipta$35$28,11316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 270 neurology providers in South Carolina.

Other neurology in Charleston

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →